Search the Newsreel

Asset Plus lifts occupancy at Munroe Lane as it eyes eventual asset sale and wind-up

Asset Plus lifts quarterly dividend on Munroe Lane lease boost

CFO of EPLUS INC (PLUS) sells 7,182 shares in Rule 10b5-1 trades

EPLUS INC's Chief Financial Officer, Elaine D. Marion, sold a total of 7,182 shares of common stock on August 3–4, 2026, through open-market transactions. These sales were executed indirectly via a revocable trust under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. …

Simulations Plus Chief Revenue Officer John Anthony DiBella II sells 1,000 shares for $18,280

Simulations Plus Chief Revenue Officer John Anthony DiBella II sold 1,000 common shares on August 3rd for $18.28 each, totaling $18,280. This transaction reduced his direct holdings to 85,140 shares. The information was generated using AI from a filing with the U.S. Securities and …

Plus Therapeutics amends bylaws to reflect corporate name change to Cerenome

Plus Therapeutics has amended its bylaws to reflect a corporate name change to Cerenome, effective August 3, 2026. The company's Nasdaq trading symbol also switched to CNSY on the same date, though the CUSIP for the common stock remains unchanged. This news brief was …

Earnings Flash (PLUS) ePlus inc. Reports Q1 Revenue $649.1M, vs. FactSet Est of $640.0M

ePlus inc. reported its Q1 revenue reached $649.1 million, surpassing FactSet's estimate of $640.0 million. The company also posted Q1 adjusted EPS of $1.28 per share, exceeding the FactSet estimate of $1.19. This financial update indicates a stronger-than-expected performance for the quarter.

Plus Therapeutics presents REYOBIQ data at neurosurgery meeting

Plus Therapeutics (PSTV) presented encouraging clinical data for its radiopharmaceutical REYOBIQ at the 2026 American Association of Neurological Surgeons Annual Scientific Meeting. The data from the Phase 1 ReSPECT-LM trial, which evaluates REYOBIQ for leptomeningeal metastases, showed a median overall survival of approximately 9 …

Keep An Eye On Star Plus Legend Holdings As Insider Stock Selling Hits CN¥393m

The Bull Case For ePlus (PLUS) Could Change Following Q1 Earnings, Payout Moves, And Share Expansion Plans - Learn Why

ePlus (NASDAQ:PLUS) Surprises With Q2 CY2026 Sales

Earnings call transcript: ePlus tops Q1 2026 estimates as AI demand lifts shares

ePlus exceeded Q1 2027 earnings and revenue expectations, driven by strong demand in AI infrastructure and security, despite challenging year-over-year comparisons. The company reported adjusted EPS of $1.28 and revenue of $649.1 million, leading to a 5.7% stock increase after hours. Management affirmed fiscal …

ePlus Q1 Fiscal 2027 Net Sales Rise To $649.1 Million

ePlus (PLUS) announced a 1.0% increase in net sales to $649.1 million for the first quarter of fiscal 2027, although net earnings from continuing operations decreased by 5.4%. The company reiterated its fiscal 2027 guidance for mid-single-digit growth in net sales, gross profit, and …

EPLUS INC 2026: Revenue $649.11M, EPS $1.16— 10-Q Summary

EPLUS INC reported its 2026 quarterly results with revenue of $649.11M, a modest increase from the prior year, while net income and diluted earnings per share saw a decline. The company's revenue growth was driven by product and managed services gains, despite a decrease …

EPLUS (PLUS) trust details Rule 144 sales and stock awards

An affiliate of an EPLUS shareholder filed a Rule 144 notice to sell common stock through Rockefeller Capital Management. The filing details prior stock awards of 5,000 shares each on several dates in 2024 and 2025. It also reports recent sales by the Elaine …

ePlus (PLUS) trust plans NASDAQ sale of 200 shares under Form 144

The Darren S Raiguel Trust, associated with ePlus (PLUS), has filed a Form 144 indicating its intent to sell 200 shares of common stock through Rockefeller Capital Management on or about August 4, 2026. The proposed sale has an indicated value of $19,582.63 and …

Earnings Flash (PLUS) ePlus inc. Posts Q1 Adjusted EPS $1.28 per Share, vs. FactSet Est of $1.19

ePlus inc. (PLUS) announced its Q1 adjusted earnings per share (EPS) of $1.28, surpassing the FactSet estimate of $1.19. The company's Q1 revenue also rose, reaching $649.1 million against an estimated $640.0 million. The report indicates a positive financial performance for the IT solutions …

Lockheed seeks US mineral supplies after Trump supply-chain push, sources say

Lockheed Martin is in talks to buy supplies of two critical minerals from U.S. mines, two sources familiar with the discussions said, as President Donald Trump pressures defense contractors to cut reliance on China. The world's largest defense contractor is negotiating with NioCorp Developments …

Simulations Plus, Inc. (SLP) CRO sells 1,000 shares under Rule 10b5-1 plan

Simulations Plus, Inc.'s Chief Revenue Officer, John Anthony DiBella II, sold 1,000 shares of common stock on August 3, 2026, at $18.28 per share through a Rule 10b5-1 trading plan. Following this transaction, DiBella directly holds 85,140 shares. The sale was executed automatically and …

ePlus in the spotlight as earnings loom after AI-fueled year

ePlus Inc. is preparing to report its first-quarter fiscal 2027 earnings, with investors focused on whether the AI infrastructure boom that fueled its previous year's success can continue. Analysts anticipate earnings of $1.19 per share on revenue of $631.35 million. Key areas of interest …

Telecom Plus (LON:TEP) Insider Phil Bunker Acquires 645 Shares of Stock

Insider Buying: Telecom Plus (LON:TEP) Insider Buys £5,611.50 in Stock

Enterprise value to revenue forward of VCPlus Limited – SGX:43E

Earnings Flash (VNP.TO) 5N Plus Inc. Reports Q2 Revenue $122.4M, vs. FactSet Est of $114.1M

Simulations Plus (NASDAQ:SLP) Stock Price Passes Above 200-Day Moving Average - Here's Why

5N Plus Inc. Reports Second Quarter 2026 Financial Results

5N Plus Inc. 2026 Q2 - Results - Earnings Call Presentation (TSX:VNP:CA) 2026-08-04

Gemma Godfrey Purchases 637 Shares of Telecom Plus (LON:TEP) Stock

Discontinued operations of PLUS THERAPEUTICS, Inc. – NASDAQ:CNSY

This article briefly reports on the discontinued operations of PLUS THERAPEUTICS, Inc. (NASDAQ: CNSY). The content is minimal, essentially just stating the fact and indicating that the market for CNSY is closed with no trades. It provides no further details regarding the reasons or …

NUVEEN CORE PLUS IMPACT FD To Go Ex-Dividend On August 14th, 2026 With 0.0895 USD Dividend Per Share

Cash flow from financing activities of PLUS THERAPEUTICS, Inc. – BOATS:CNSY

This article focuses on the cash flow from financing activities for PLUS THERAPEUTICS, Inc. (CNSY) as displayed on TradingView. It provides a financial overview of the company, indicating that the market is currently closed with no trades. The content primarily highlights financial data and …

Total common shares outstanding of PLUS THERAPEUTICS, Inc. – BOATS:CNSY

This article provides the total common shares outstanding for PLUS THERAPEUTICS, Inc. (CNSY) within the TradingView platform. It details the company's financials and offers various market data tools and community features available on TradingView. The content is primarily a data point surrounded by the …

Price to sales ratio of PLUS THERAPEUTICS, Inc. – BOATS:CNSY

This article provides the price to sales ratio for PLUS THERAPEUTICS, Inc. (CNSY) on the Blue Ocean Alternative Trade System (BOATS). It appears to be a stub or a data point, as the market is closed and no trades are recorded. The content primarily …

Simulations Plus (SLP) insider schedules 3,000-share Rule 144 sale and details 10b5-1 trades

Simulations Plus (SLP) insider John Anthony DiBella II has filed a Rule 144 notice to sell 3,000 common shares, valued at $54,690, which originated from previously exercised options. The filing also details three separate 10b5-1 plan sales, each for 1,000 shares, that occurred in …

PLUS THERAPEUTICS, Inc. Financial Statements – NASDAQ:CNSY

This article provides financial information for PLUS THERAPEUTICS, Inc. (NASDAQ: CNSY), a clinical-stage pharmaceutical company focused on rare cancer treatments. It details the company's profile, including its mission, founding, and leadership, but notes a lack of available market capitalization, revenue, and net income data. …

ePlus (NASDAQ: PLUS) trust plans 1,668-share sale after prior 2,818-share trade

A trust associated with ePlus (NASDAQ: PLUS) is planning to sell 1,668 common shares valued at $158,659.50 on or after August 3, 2026. This follows a previous sale of 2,818 shares by the same trust on July 29, 2026, which generated $268,336.48. The shares …

75% Efficiency Achieved: Capstone Energy+ Deploys 2 MW CHP at Scripps Mercy

Capstone Energy+ has installed two C1000 Signature Series microturbines at Scripps Mercy Hospital in San Diego, providing two megawatts of combined heat and power (CHP) with 75% efficiency. This system will ensure reliable on-site electricity, capture waste heat for facility heating, and offer island-mode …